 |
|
|
| |
HIV Attachment Inhibitor Fostemsavir / BMS-663068, GSK3684934
|
| |
| |
Fostemsavir (BMS-663068) is an experimental HIV entry inhibitor and a prodrug of temsavir (BMS-626529).
Fostemsavir
Other Names: BMS-663068, GSK3684934, fostemsavir tromethamine, prodrug of BMS-626529, prodrug of GSK2616713, prodrug of temsavir
Drug Class: Entry Inhibitor
Registry Number: 864953-29-7 (CAS)
Chemical Name: Piperazine,
1-benzoyl-4-((4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-((phosphonooxy)methyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)oxoacetyl)-
Company: ViiV Healthcare
Phase of Development: III
HIV-1 Attachment Inhibitor Prodrug BMS-663068:
Interactions with Rifabutin, with or without Ritonavir, in Healthy
Subjects....http://www.natap.org/2015/IAS/IAS_64.htm
ViiV Healthcare to acquire Bristol-Myers Squibb HIV R&D assets
- HIV attachment & maturation
inhibitors....http://www.natap.org/2016/HIV/010816_01.htm
The late stage R&D assets include an attachment inhibitor (BMS-663068) investigated in Phase III as a breakthrough therapy candidate for heavily treatment-experienced patients. The other two assets are maturation inhibitors. The first one (BMS-955176) is in Phase IIb research for treatment-naïve and treatment-experienced patients, with the second (BMS-986173) being a back-up candidate. A transitional services agreement will be in place to manage the transfer of the assets following completion of the deal with Bristol-Myers Squibb.
The acquisition of Bristol-Myers Squibb's HIV discovery programmes includes a novel biologic treatment with a triple mechanism of action (BMS-986197), a maturation inhibitor, an allosteric integrase inhibitor and a capsid inhibitor. As part of the agreement, a number of Bristol-Myers Squibb drug discovery employees will be offered the opportunity to transfer to ViiV Healthcare. Bristol-Myers Squibb will continue to provide some support to the discovery programmes pursuant to a service agreement.
|
| |
|
|
|
|
|
